In the era of personalized medicine, there is an urgent need for in vivo techniques able to sensitively detect and quantify molecular activities. Sensitive imaging of gamma rays is widely used; however, radioactive decay is a physical constant, and its signal is independent of biological interactions. Here, we introduce a framework of previously uncharacterized targeted and activatable probes that are excited by a nuclear decay-derived signal to identify and measure molecular signatures of disease. We accomplished this by using Cerenkov luminescence, the light produced by b-particle-emitting radionuclides such as clinical positron emission tomography (PET) tracers. Disease markers were detected using nanoparticles to produce secondary Cerenkov-induced fluorescence. This approach reduces background signal compared to conventional fluorescence imaging. In addition to tumor identification from a conventional PET scan, we demonstrate the medical utility of our approach by quantitatively determining prognostically relevant enzymatic activity. This technique can be applied to monitor other markers and represents a shift toward activatable nuclear medicine agents.
In the era of personalized medicine, there is an urgent need for in vivo techniques able to sensitively detect and quantify molecular activities. Sensitive imaging of gamma rays is widely used; however, radioactive decay is a physical constant, and its signal is independent of biological interactions. Here, we introduce a framework of previously uncharacterized targeted and activatable probes that are excited by a nuclear decay-derived signal to identify and measure molecular signatures of disease. We accomplished this by using Cerenkov luminescence, the light produced by b-particle-emitting radionuclides such as clinical positron emission tomography (PET) tracers. Disease markers were detected using nanoparticles to produce secondary Cerenkov-induced fluorescence. This approach reduces background signal compared to conventional fluorescence imaging. In addition to tumor identification from a conventional PET scan, we demonstrate the medical utility of our approach by quantitatively determining prognostically relevant enzymatic activity. This technique can be applied to monitor other markers and represents a shift toward activatable nuclear medicine agents.
Radioisotopes play a fundamental part in life sciences and clinical medicine by enabling unparalleled sensitivity in applications to study and identify disease. However, the physical phenomenon of radioactive decay cannot be switched 'on' and 'off '; radiolabeled molecules are always detectable regardless of their biological interactions (Fig. 1a) . This has so far excluded nuclear agents from use as 'activatable probes' , or agents whose signal is amplified upon interaction with their biologic target. Clinical radiotracers such as [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) and radiotracer genetic reporter strategies 1,2 indirectly indicate metabolic activity through accumulation and are plagued by high background signals.
Activatable optical imaging and magnetic resonance imaging approaches have visualized enzymatic activity implicated in inflammation and cancer aggressiveness and progression [3] [4] [5] . Ideally, molecular imaging accurately reports activity of an enzyme or other biological event at a disease site. Fluorescence or bioluminescent strategies are powerful but are inherently nonquantitative, with instrument-dependent results. Likewise, magnetic resonance reveals only relative relaxivity changes dependent on an unknown probe concentration 6 . Similar caveats hold for newer approaches involving PET 7 .
Cerenkov luminescence is light generated when charged particles (for example, β − or β + particles emitted upon radioactive decay) exceed the speed of light in a dielectric medium ( Fig. 1b) . First observed over a century ago 8 , visualization of Cerenkov luminescence was only recently achieved in vivo 9 . Advantages of Cerenkov luminescence include higher throughput, cost savings and greater surface resolution compared to nuclear imaging ( Supplementary  Fig. 1) . Produced by many clinically approved tracers, it offers a facile route for translation of optical molecular imaging 10, 11 .
Here, we describe a new imaging strategy, secondary Cerenkovinduced fluorescence imaging (SCIFI), that uses nanoparticles to achieve activatable imaging through biologically specific fluorescent conversion of Cerenkov luminescence (Fig. 1c) . Activatable imaging agents utilizing this principle were then used for the detection of clinically relevant enzymatic activity. We overcame issues of target specificity, background noise, tracer clearance and quantification through unique combinations of PET and nanoparticle Cerenkov luminescence imaging. We hypothesize that radionuclide-based activatable imaging will enable specific imaging of disease signatures for the benefit of biomedical research and clinical diagnostic accuracy.
RESULTS

Fluorescence and Cerenkov-induced fluorescence
We used an in vitro phantom model to demonstrate Cerenkov luminescence conversion to a longer wavelength by a fluorophore. We mixed a Cerenkov luminescence source (gallium-68) with fluorescein (FAM) in a quartz vial and submerged it in a medium that scatters and absorbs light similar to tissue to compare conventional fluorescence with SCIFI ( Fig. 2a,b) . By defining regions of interest over the source and background, we found that the incident excitation light (required for conventional fluorescence) adversely affected the signal-to-background distinction (Fig. 2c) . In contrast, internal excitation by the radionuclide for SCIFI markedly decreased the nonspecific signal, resulting in greater signal-to-background values (Fig. 2d) . These results persisted at increasing depth, where we had assumed that the lower photon flux of the Cerenkov source would diminish any advantage.
Skin autofluorescence and reflection from excitation light complicate conventional fluorescence imaging. To mimic a tumor xenograft, we subcutaneously implanted [ 18 F]FDG in tandem with fluorescein in a capillary tube. The exciting light for conventional fluorescence, which must first penetrate into the tissue to excite the fluorophore, increased background signal ( Fig. 2e-g) . Following quantification, the signal-to-background values for SCIFI were 5.7 times greater than that of the conventional imaging ( Fig. 2h) . These results indicate that sensitive and low-background acquisitions are advantages of SCIFI despite the low intensity of Cerenkov light.
Multispectral codependent imaging of tumor markers PET enables tomographic, whole-body and quantitative imaging but can evaluate only a single tracer per study. We sought to achieve multiparameter readout of the molecular pathophysiology of disease by converting Cerenkov luminescence from PET tracers with spectrally distinct fluorophores in addition to acquiring PET data.
The continuous Cerenkov luminescence spectrum is primarily ultraviolet and blue, which is less than optimal for in vivo imaging. However, this spectrum can excite many widely used fluorophores. Therefore, we pursued Cerenkov luminescence-excited fluorescent nanoparticles (quantum dots 12, 13 ) emitting light in the deeper tissue-penetrating near-infrared range ( Fig. 3a,b ). We used [ 18 F]FDG to evaluate emissions from an array of fluorophores ( Fig. 3c ; an unmasked, equalized scale image is presented as Supplementary Fig. 2) .
The agents tested can be used to evaluate SCIFI across a broad range of spectral wavelengths (Supplementary Tables 1 and 2).
Analysis indicated that the excitation profile of the fluoresceinbased FITC and quantum dots is optimal for SCIFI, particularly quantum dot 605 (QD605) ( Fig. 3c) . Cyanine dyes are less well suited for SCIFI owing to excitation outside of the main Cerenkov luminescence emission 14 . The three quantum dots that we evaluated possess distinct fluorescence emission characteristics for SCIFI in vitro (Supplementary Fig. 3a ) and in vivo when contained in Matrigel pseudotumors ( Supplementary Fig. 3b ).
SCIFI enables multispectral, deep-tissue and potentially targeted imaging from the radiotracer source. We hypothesized that we could independently target a clinical radiotracer and quantum dot to simultaneously demonstrate multiparameter imaging of tumor signatures with high tumor-to-background values. To this end, 89 Zr-labeled deferoxamine-trastuzumab ( 89 Zr-DFO-trastuzumab; undergoing clinical trial for metastatic breast cancer detection 15 ) was administered to mice bearing HER2/neu-positive tumor xenografts (BT-474). Uptake of 89 Zr-DFO-trastuzumab (6 h after injection) was followed Figure 1 The conventional PET tracer principle and the development of agents that fluorescently convert the Cerenkov radiation optical decay signal. (a) PET enables high-sensitivity and quantitative imaging of whole-body tracer distribution. Unfortunately, radioactive probes are detectable regardless of their biological interactions, which can include binding, degradation or no change to the probe. This results in high background signal that is indistinguishable from accumulated probe. (b) Cerenkov luminescence is a result of charged particles moving through a dielectric medium faster than the speed of light in that medium. The high-energy particles polarize water molecules along their path. When these polarized molecules relax, they release a continuous-wavelength luminescence centered in the blue. (c) This phenomenon can be harnessed to provide functional information regarding a radiotracer's in vivo fate. We can augment the depth of penetration of the blue-weighted light by using Cerenkov luminescence to excite fluorophores. SCIFI can also be used in conjunction with activatable probes. This approach affords quantitative PET radiotracer information in addition to fluorescence reports of disease-specific ligands and activities. npg by PET and Cerenkov luminescence imaging. As expected, the targeted radiotracer revealed the presence of HER2/neu expression of the xenografts (Fig. 3d) .
We next injected QD605 targeting the α v β 3 integrin (cyclic Arg-Gly-Asp (cRGD)-QD605) or control QD605 (cyclic Arg-Ala-Asp (cRAD)-QD605). SCIFI signal was generated by excitation of the colocalized 89 Zr-DFO-trastuzumab and cRGD-QD605 but was absent in the nonspecific control cRAD-QD605 ( Fig. 3d) . Selective codependent signal can be observed noninvasively over the experiment's duration, showing injection, binding and clearance ( Fig. 3e) .
As there was no autofluorescence or reflection in the absence of external excitation, background signal was minimal, and we observed greater than four times the signal from the targeted probe at 2 h ( Fig. 3f) . SCIFI provided information on α v β 3 expression in addition to the quantitative radiotracer uptake data assessing HER2 expression (across both groups at 18 h after injection, 11.56 ± 1.08% injected dose per gram of tissue). Having established that PET and SCIFI can be used for the determination of multiple disease-relevant ligands concomitantly, we sought to evaluate enzymatic activity through in vivo activation of a SCIFI probe.
In vivo imaging of matrix metallopeptidase-2 enzymatic activity
We conjugated gold nanoparticles (AuNPs) to FAM-labeled peptides as a biocompatible activatable platform to measure disease-relevant enzymes (Fig. 4a) . The peptide sequence IPVSLRSG is cleaved at the Ser-Leu bond 16 by the gelatinase matrix metallopeptidase-2 (MMP-2; implicated in cancer aggressiveness [17] [18] [19] ). Coupling of the FAMlabeled peptide to the AuNP surface, AuNP-IPVSLRSG-FAM, leads to quenching of FAM fluorescence 20 . Cleavage by MMP-2 releases FAM, and its emission becomes detectable ( Fig. 4b) . We hypothesized that the [ 18 F]FDG Cerenkov luminescence-excited fluorescence ( Fig. 4c ) could be spectrally separated from Cerenkov luminescence to quantify the activation of the probe and therefore give a readout for both glycolytic ([ 18 F]FDG) and enzymatic (MMP-2) activity.
Mice bearing MMP-2-overexpressing xenografts (SCC7) and those with xenografts expressing a low level of MMP-2 (BT20) (ref. 21) were injected with [ 18 F]FDG and AuNP-IPVSLRSG-FAM. [ 18 F]FDG had slightly preferential but nonsignificant (P > 0.2) uptake in the faster-growing SCC7 tumors by PET ( Fig. 4d) . Optical imaging (open, no filter) recapitulated the negligible difference (P > 0.1) between tumor types ( Fig. 4e) filter for FAM revealed a statistically significant activated signal (P < 0.001) solely in SCC7 tumors ( Fig. 4f) . We performed X-ray computed tomography and dark-field microscopy to eliminate the possibility that the difference was due to differential probe distribution (Online Methods and Supplementary Fig. 4) . Thus, successful SCIFI by MMP-2 cleavage provides molecularly specific information atop the indiscriminate [ 18 F]FDG uptake through PET. Next, we quantified enzymatic activation of the nanoparticle probe. PET accurately reveals the actual radiotracer concentration. This can be used with the integrated Frank-Tamm equation to calculate the amount of Cerenkov luminescence produced in a defined spectral window in tissue 22 . We first separated the filtered signal (510-575 nm) from its two components: the activated SCIFI probe (FAM) and the remaining Cerenkov luminescence contribution ( Fig. 4g ; additional information in Supplementary Fig. 5 , Supplementary Methods and Online Methods). We determined the number of activated probes using a calibration curve of Cerenkov luminescence-excited FAM.
In the enzyme-expressing tumor, this yielded an average of 6.23 pmol of activated probe, whereas activation in the control tumor was 1.56 pmol (P < 0.001) ( Fig. 4h) . We also analyzed the expression and gelatinolytic activity of MMP-2 from cell culture supernatant and the tumors. Expression of activated MMP-2 was greater on a per-totalprotein basis in the SCC7 line compared to the BT20 model in both culture supernatant (31.8 ng to 5.83 ng, respectively) and lysed tumors (1.16 ng to 0.187 ng, respectively, Fig. 4i ). Likewise, zymography of representative tumor lysates revealed a greater enzyme activity in the SCC7 (2.21 ng) than in the BT20 xenograft (1.49 ng) when compared to activated MMP-2 standards (Fig. 4j) . Relative differences between quantitative western blot data, as well as the enzyme activity, correlate well with in vivo SCIFI assessment of protease activation.
DISCUSSION
These results establish that targeted and activatable fluorescent probes can transfer and spectrally shift the optical radionuclide decay signal npg of Cerenkov radiation from clinical radionuclides. SCIFI distinguishes, with high specificity, low background and high resolution (superficially), the presence of multiple molecular signatures of disease. This inherently dual-modality approach first uses systemically administered agents to achieve whole-body quantitative radionuclide distribution by PET. Multiple molecular features of the tumor environment are then captured using fluorescent nanoparticle or organic dye sensors excited by the radiotracer. This approach has the potential to create a new application space for nuclear molecular imaging. Quantitative PET signal indicates glycolytic activity (for example, in malignancies), and this remains unaltered by the optical probes. SCIFI reveals biomolecularly specific information regarding tumor biology such as marker expression (for example, of α v β 3 ). This work demonstrates a new approach for using radiotracers as platforms for activatable agents, as we show quantitative readout of probe activation by an enzyme (for example, MMP-2). This yields complementary information otherwise unobtainable with PET alone, which cannot distinguish signal from multiple tracers or between activated and nonactivated agent. Multispectral SCIFI was illustrated through the simultaneous excitation of multiple fluorophores in vitro (Fig. 2b) and of three reporters with a single administration of [ 18 F]FDG in vivo (Supplementary Fig. 3 ).
Using this approach, SCIFI visualized both HER2/neu and α v β 3 to simultaneously give a readout of multiple disease-relevant markers. This required no external excitation of agents; antibody and quantum dots were detected as a result of codependent Cerenkov luminescence and Cerenkov-induced fluorescence, respectively. SCIFI depends on the distribution of the targeted radioactive and optical probes that require biospecific homing (through trastuzumab and RGD peptide, respectively). Unlike other activatable approaches, such as bioluminescence resonance energy transfer 23,24 , the systems described here do not require administration of immunogenic proteins (for example, luciferase and GFP) or foreign enzyme substrate (for example, luciferin or coelenterazine). SCIFI avoids reflection and autofluorescence artifacts from external excitation and achieves minimal background signal by using internal illumination through Cerenkov luminescence.
Successful application of SCIFI did not require toxic quantum dot particles, as it was also accomplished with inert AuNP and approved fluorescent dye. Activated fluorescent conversion of Cerenkov luminescence from nonspecific [ 18 F]FDG resolved specific enzymatic expression of distinct tumors. Notably, tumors or sites of inflammation are often identified solely through increased glycolysis and accumulation of [ 18 F]FDG, irrespective of other defining molecular markers 25 . Noninvasive distinction of tumor-to-tumor molecular heterogeneity, quantitatively, is a crucial step toward personalization of diagnosis and patient management.
Cerenkov luminescence intensity depends on the energy of the emitted charged particle and the properties of the surrounding medium 26 . The low amount of Cerenkov light (relative to fluorescence) can be detected by high-sensitivity cameras 9 , but translation to the clinic presents technical challenges, including strict restriction of ambient light, background high-energy photon and cosmic ray detection (Supplementary Fig. 6 ) and tissue depth-dependent signal attenuation. Higher β-particle energy emitters produce more Cerenkov luminescence per decay (such as 68 Ga and 89 Zr compared to 18 F) and can be used to overcome some signal level concerns. Application of specific instrumentation (for example, adapted endoscopy) can also be expected to reduce the difficulty of translation 27, 28 . Whole-body optical imaging is probably not feasible; however, hybrid SCIFI-PET can overcome some depth and imaging issues seen with conventional fluorescence.
Offering an impact beyond small-animal imaging, clinically approved tracer and fluorophore combinations lessen regulatory issues associated with clinically untested compounds. Regulatory approval is an issue that has hindered translation of conventional fluorescent agents. Requiring only sensitive camera equipment, SCIFI could be translated to the clinic in diagnostic and intraoperative settings with minor deviation from current protocols.
The systems used here enable target-specific and functional investigation of multiple biological signatures in vivo through the fluorescent conversion of a radioactive decay signal. Clinical radiotracers, in concert with diagnostic and therapeutic nanoparticle sensors targeted to the ever-expanding library of disease markers, lend this new methodology to an array of basic and potentially clinical applications. The synergistic advantages of PET, in addition to Cerenkov optical imaging, provide impetus for further investigation.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Chemicals. All materials were purchased from Thermo Fisher Scientific (Waltham, MA) unless otherwise noted. Quantum dots (QD565, QD605 and QD800; amino-PEG-ITK) were purchased from Invitrogen. Cy5.5-NHS and Cy7-NHS were purchased from GE Healthcare. All peptides were obtained from Anaspec. Quantum dot conjugates and AuNP were synthesized as described below.
Radionuclides and tracers. [ 18 F]FDG was supplied by IBA Molecular with a specific activity of >41 MBq/µmol (>11 mCi/µmol) and a radiochemical purity of >98%. The tracer was obtained through the Radiopharmacy of the Department of Nuclear Medicine at Memorial Sloan-Kettering Cancer Center (MSKCC). 0.1 N HCl 68 Ga elute was obtained from a 68 Ge/ 68 Ga generator. 89 Zr was obtained from the Radiochemistry Core Facility. It is produced in high radiochemical and radionuclidic purity through the 89 Y(p,n) 89 Zr transmutation reaction on an Ebco TR19/9 variable-beam energy cyclotron (Ebco Industries) 29 . 89 Zr was purified and used to label the monoclonal antibody trastuzumab (Genentech) as previously described 30 .
Nanoparticle probes. QD605 was used as the basis to construct targeted and activatable fluorescent nanoparticle probes. This is a near-infrared agent that adequately matches the 600 nm (20-nm bandwidth) bandpass filter on the IVIS 200 system. For targeted in vivo imaging, α v β 3 integrin-targeting particles were linked to Cyclo-(RGDyK), and control particles were coupled to Cyclo-(RADfK) 31 . QD605 was coupled to peptides following activation with disuccinimidyl suberate in pH 8.5 Na 2 CO 3 buffer. After 1 h incubation, the particles were purified with a YM-50 filter (Millipore) and functionalized with the peptide.
Citrated-capped gold nanoparticles (AuNPs) were synthesized by dissolving 50 mg of hydrogen tetrachloroaurate trihydrate in 150 mL of deionized H 2 O. Sodium citrate (15 mL, 40 mM) was added to a boiling solution of the chlorauric acid. Unreacted components were removed by centrifugal purification before conjugation. The peptide Cys-(PEG) 2 -IPVSLRSG-(PEG) 2 -Lys (5-FAM)-Gly-Lys(DOTA) was added in 100× molar excess to the particles, mixed overnight at 15 °C, and then purified through repeated washes in saline on a YM-50 filter. Peptide-labeled particles were fully soluble in physiological buffers at pH 7.4.
Spectrophotometry.
All probes and radionuclides were characterized for absorbance and luminescent properties using a SpectraMax M5 (Molecular Devices). All samples were read using a quartz cuvette (volumes between 250 and 1,000 µL). All quantum dot fluorescence profiles were obtained with excitation at the 488 nm laser line. Cerenkov-excited fluorescence profiles of the quantum dots were obtained by co-mixing the particles with 68 Ga (270 µCi, 10 MBq) and capturing the luminescence spectra.
Animal experiments.
All animal experiments were conducted in compliance with Institutional Animal Care and Use Committee guidelines and the Guide for the Care and Use of Laboratory Animals 32 . All animal procedures were performed under anesthesia by inhalation of a 1-4% isoflurane-air mixture (Baxter Healthcare). Animals were obtained from Harlan Laboratories. Athymic nu/nu mice between the ages of 10 and 16 weeks were used for all experiments. Female mice were used for the 89 Zr-DFO-trastuzumab studies (approximately 260 µCi per mouse, 9.62 MBq), and male mice were used in all other experiments.
Cerenkov luminescence imaging. Cerenkov luminescence images were obtained using the IVIS 200 run under Living Image 4.2 (Caliper Life Sciences). This system uses a cryo-cooled electron-multiplying charge-coupled device for high-sensitivity detection of low light intensity sources. Filters provided with the device determined to some degree the fluorophores and quantum dots tested. All images were quantified in the Living Image software (version 2.6).
For the determination of the signal-to-background ratio of Cerenkov luminescence in a tissue-mimic phantom, 150 µCi or 5.55 MBq of 68 Ga activity was placed in a glass vial filled with glycerin. For evaluation of dye and quantum dot particles activation properties, 14.8 MBq (400 µCi) of [ 18 F]FDG (200 µL in an Eppendorf tube) was used. The source was surrounded by 100 µL volume solutions of water, FITC, Cy dyes (at 1 mM) and quantum dot (4 µM) samples. The subcutaneously implanted [ 18 F]FDG (55 µCi, 2.04 MBq) was placed in a capillary tube, with or without co-mixture with fluorescein. For in vivo excitation of multiple quantum dots simultaneously, a dose of [ 18 F]FDG (660 µCi, 24.42 MBq) was administered to the animal immediately before imaging.
Phantom imaging for SCIFI and fluorescence comparison. In vitro phantom. A vial (0.7-mm inner diameter × 2.5 cm in length) was filled with a mixture of glycerine (refractive index of 1.47), radionuclide (freshly eluted gallium-68 balanced to pH 7.4 with sodium carbonate) and fluorophore (FAM). The final concentration of fluorophore was 0.5 mM, and the starting activity of the 68 Ga was 150 µCi (5.55 MBq). The vial was placed in a black container in a tissue scattering and absorbing phantom composed of Intralipid (Fresenius Kabi) and India ink (Fisher Scientific) 33 . Imaging was performed on the IVIS 200 (Calipers), using the GFP excitation (for fluorescence) and emission filters, and all results were decay-corrected to the initial acquisition. Increasing volumes of the scattering and absorbing medium were added, and the depth calculated from the dimensions of the container. Images were acquired for 30 s. Regions of interest were drawn around the vial when it was exposed (before being submerged) along with multiple regions of interest at the corners of the container. Background subtracted signal-to-background measurements were made off of these regions using average radiance (ph s −1 cm −2 sr −1 ).
In vivo phantom. A capillary tube was filled with saline, FAM (0.5 mM) and [ 18 F]FDG (115 µCi, 4.26 MBq). This mixture was then subcutaneously implanted into a euthanized mouse. Images were acquired for 60 s. The experiment was performed in triplicate.
Fluorescence imaging and SCIFI. For in vivo multispectral conventional fluorescence imaging, the Maestro was used. Multispectral SCIFI was done with acquisitions on the IVIS 200 in the 560 and 600 nm bandpass and indocyanine green filters. Luminescence images without cosmic-ray correction were imported into ImageJ, and outliers were then removed. The filterspecific images were false colored and then overlaid on a white light image of the animal. Individual channel acquisitions can be found in Supplementary  Figure 5b . Activatable SCIFI imaging to detect MMP-2 enzyme activity was performed with the GFP filter using the IVIS 200. The luminescence images were exported and processed in ImageJ, as above.
PET. Mice were imaged in a prone position using either an R4 or Focus 120 microPET-dedicated small-animal PET scanner (Concorde Microsystems) with an energy window of 350-700 keV and coincidence timing window of 6 ns. For [ 18 F]FDG studies, images were acquired at 60 min after administration over a period of 15 min. Times of acquisition for 89 Zr studies were also 15 min in length at the post-injection times noted.
The list-mode data were sorted into two-dimensional histograms by Fourier rebinning, and images were reconstructed by filtered back-projection using a ramp filter with a cutoff frequency equal to the Nyquist frequency in either a 128 × 128 × 64 matrix (R4) or a 128 × 128 × 94 matrix (Focus 120). Normalized image data (i.e., corrected for nonuniformity of scanner response) was corrected for dead-time count losses and physical decay to the time of injection.
Count rates in the reconstructed images were converted to activity concentration and subsequently percentage of injected dose per gram of tissue using a system calibration factor (µCi per mL per c.p.s. per voxel) derived from imaging a mouse-size phantom filled with a uniform aqueous solution of [ 18 F]FDG. The reconstructed images were visually examined and analyzed using ASIProVM (Concorde Microsystems) with window and level settings adjusted for maximal tumor visibility. Regions of interest were manually drawn to circumscribe tumors. The mean percentage injected dose per gram of body weight within the structure was computed from the volume of interest. For [ 18 F]FDG acquisitions, animals were deprived of food for between 4 and 6 h before imaging.
Quantification model. Quantification of the dye molecules that were activated was achieved through observed measurements and modeling. We determined npg the number of Cerenkov photons generated from the radioactivity that accumulated in a tumor by integrating the Frank-Tamm equation (below) for the β-particle energy distribution of 18 F over the Cerenkov threshold between the relevant wavelengths 22 . These are the emission regions (510-570 nm) of the FAM or GFP filter.
Here, β is the velocity of the particle relative to the speed of light, n is the refractive index, dN/dx is the number of photons produced per centimeter path length, α is the fine-structure constant and the λs denote a spectral range. From the PET quantification of activity, we can determine the number of photons produced in the 510-570 nm range. A tissue refractive index of 1.4 (estimated from the literature) and the activity as measured from PET gives a value of 0.4206 photons per becquerel. This was then adjusted for attenuation using an experimentally determined factor derived from observed photon flux in the tumors with [ 18 F]FDG 72 h before the activation experiments. Subtracting this value from the observed tumor photon flux yields the contribution from the active fluorescent probe alone. Using an experimentally determined standard curve of the active probe (AuNP and FAM) in saline (n = 1.33) and [ 18 F]FDG, we can determine the number of activated FAM molecules from the observed SCIFI channel.
X-ray computed tomography imaging. Imaging for detection of AuNP uptake was performed using a microCAT II (ImTek) scanner operating at 60 kVp and 0.8 mA with 2-mm aluminum filtration. Animals injected with the AuNP and without were scanned. All animals bore dual-shoulder xenografts of BT20 (MMP-2 − ) and SCC7 (MMP-2 + ) tumors. Images were acquired with a 93-µm isotropic resolution. A global region of interest was drawn around the animal and zero-filled to exclude edge and bed signal. Data for five sequential slices through each tumor were evaluated for intensity in each tumor, paraspinal muscle and air (analyzed in ImageJ). A reconstruction using the ImageJ threedimensional volume viewer plugin was used to create the three-dimensional slab view.
Quantitative western blotting. Cell supernatants were obtained using serum-free medium from BT-20 and SCC7 cultures and concentrated using Amicon Ultra centrifugal filters (5,000 MWCO). BT-20 and SCC7 tumors were lysed using 50 mM Tris pH 7.5, 150 mM NaCl and manually homogenized. Concentrated cell supernatants, tumor lysates and MMP-2 recombinant protein (Enzo Life Sciences) were activated by 1 mM 4-aminophenylmercuric acetate for 16 h at 37 °C (ref. 34) . Cell supernatant (50 µg) and tumor lysate (30 µg) concentrations were determined by the BCA assay. Samples were separated on NuPAGE 4-12% Bis-Tris gels and electrophoretically transferred to nitrocellulose alongside MMP-2 standards (4, 10 and 40 ng; #BML-SE503). For MMP-2, membranes were incubated with anti-MMP-2 (Abcam; #ab37150; 1:1,000) followed by donkey anti-rabbit 680RD (Licor; #926-68073; 1:1,000), and the loading control was stained with anti-β-actin (Sigma; #A1978; 1:1,000) followed by goat anti-mouse (Licor; #926-68070; 1:5,000). Blocking was performed in Odyssey Blocking Buffer (Licor), and the membranes were then imaged and analyzed using the Odyssey Infrared Imaging System (Licor) and ImageJ.
Quantitative zymography. Unconcentrated cell supernatants and tumor lysates were prepared as above, and gel loadings were determined by BCA assay (5 µg and 15 µg for cell supernatants and tumor lysates, respectively). Samples were then loaded onto 10% Zymogram (gelatin) Gels (Life Technologies) alongside 4-aminophenylmercuric acetate-activated MMP-2 standards (250 pg to 20 ng) and run at 110V at 4 °C for 3.5 h. Gels were incubated in renaturing buffer (2.5% Triton-X 100) for 30 min at room temperature and transferred to developing buffer (50 mM Tris pH 8, 5 mM CaCl 2 , 200 mM NaCl, 0.02% Brij) at 37 °C for 16-20 h. Following this treatment, gels were stained in Coomassie blue for 2-3 h and then destained to resolve digested (white) bands. Zymographies were finally imaged and analyzed using the ImageStation 4000R Pro (Carestream) and ImageJ.
Dark-field microscopy. Approximately 1 h after probe was injected and imaged, animals were killed and tumors removed. The tissue was embedded in OCT and sectioned at 10-µm thickness. Tissue was either dehydrated and imaged using dark-field microscopy or stained for H&E using conventional microscopy. For dark-field imaging, a DarkLight slide illuminator mounted onto the slide stage of a Nikon Eclipse was used. H&E imaging was performed on a NikonTi inverted microscope. A 10× objective was used and images were captured on a SPOT RT camera (Diagnostic Instruments). For analysis, the number of particles or particle clusters was counted in ImageJ averaged over ten fields.
Phantom imaging for PET and Cerenkov luminescence resolution.
A miniature Jaczeck phantom was filled with a mixture of activity (gallium-68 255 µCi, 9.43 MBq) dissolved in 15:1 saline/ethanol. The diameters of the rods in the phantom were 1.0 to 1.5 mm in 0.1-mm increments, arranged in six sextants. The core is a 2-mm central pillar. Imaging of the phantom on the small-animal imaging PET (R4, Concorde Microsystems) was completed following acquisition of 2.2 × 10 7 events. The image set was reconstructed without attenuation correction using the maximum a priori algorithm, which incorporates knowledge about the scanner's system matrix. A profile through the phantom was drawn and the intensity values plotted (ASI Pro VM Software, Concode Microsystems).
White light photography and Cerenkov luminescence images were acquired using the XR-Mega10Z camera with Schneider f0.95 lens in a custom-designed light-tight box (Stanford Photonics). The XR-Mega10Z is a dual-microchannel plate gain-stage (GaAsP)-intensified camera (Sony XX285 sensor). Triplicate acquisitions were acquired and analyzed using the Piper software suite (Stanford Photonics). The decision to use the XR-Mega10Z was motivated in part to use alternative hardware to the IVIS systems (which have, to date, been the only hardware used to image Cerenkov radiation in small animals). An optically transparent vessel of known dimensions was placed above the resolution phantom. Increasing volume of scattering and absorbing tissuemimic liquid was added to simulate increasing tissue depth. Decay-corrected intensity profiles, oriented identical to the PET acquisition, were drawn for each acquisition.
Background radiation detection. To evaluate the role of high-energy photons emitted from Cerenkov sources, we analyzed signals from a well filled with activity in an opaque black 24-well microplate (Grenier) with and without coverage by an opaque covering and with and without so-called Cosmic ray correction (CRC). CRC is performed to remove signal from extraterrestrial high-energy particles that register on sensitive optical imaging equipment. These interactions with a charge-coupled device (IVIS 200) or intensifier screen (XR-Mega10Z) are detected as hot pixels with large signals. As described by the instruction manual for the IVIS 200, the Living Image software searches for isolated high-amplitude hot pixels and replaces them with collective average of surrounding pixels.
Plates were filled with [ 18 F]FDG at 99.28, 12.59 and 1.10 MBq and diluted to 650 µL of total volume using deionized water. The plates were imaged at the maximum field of view of the system for 1 min. Subsequently, the samples were covered with ten sheets of black paper (Stratmore Artagain 400 Series Coal Black Drawing Paper). Signal from the well and background with and without covering were analyzed following decay correction of the signals.
As the IVIS imaging system performs automated background and CRC, we further investigated manual hot-pixel removal. To this end, luminescence images of PC3 tumor-bearing mice imaged 70 min after 7.12 ± 0.07 MBq retro-orbital administration of [ 18 F]FDG were imported into ImageJ. Two hot-pixel filtering functions were used. In the first, a selective median filter that replaced the value of a pixel if it deviated from the median (in a two-pixel radius) by greater than a given threshold (75 arbitrary units) by that median value. The second technique was to apply a median filter that replaced each pixel with the median value of the pixels surrounding it in a 3 × 3 neighborhood. No background luminescence or read bias correction was applied to these images, and thus the units remain uncorrected arbitrary units.
Additionally, in the case of the high frame rate XR-Mega10Z (120 fps), realtime removal of Cosmic ray event-containing frames can be performed. This technique was effectively used to remove any high-energy photons emitted npg
